We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bayer Wins EC Approval to Expand Kerendia in Heart Failure Treatment
Read MoreHide Full Article
Key Takeaways
Bayer secured EU approval to expand Kerendia for heart failure patients with LVEF greater than 40%.
Phase III FINEARTS-HF showed reduced CV death and heart failure events vs placebo.
Kerendia sales hit 829M euros in 2025, rising 79% and supporting pharma unit growth.
Bayer (BAYRY - Free Report) announced that the European Commission ("EC") has approved a label expansion of Kerendia (finerenone) in the European Union ("EU").
The drug, a selective, non-steroidal mineralocorticoid receptor antagonist (nsMRA), is now approved in the EU for the treatment of adults with heart failure (HF) with left ventricular ejection fraction (LVEF) ≥40%, i.e. HF with mildly reduced (HFmrEF) or preserved LVEF (HFpEF).
We remind investors finerenone is already marketed as Kerendia—or as Firialta in certain countries—and is approved in more than 100 countries, including China, Europe, Japan, and the United States, for the treatment of adults with chronic kidney disease (CKD) associated with type II diabetes (T2D).
Bayer Aktiengesellschaft Price, Consensus and EPS Surprise
The EC’s decision is based on results from the phase III FINEARTS-HF study, which demonstrated that finerenone significantly reduced the composite endpoint of cardiovascular death and total (first and recurrent) heart failure events, including hospitalizations and urgent visits, compared with placebo on top of standard therapy.
Heart failure affects more than 64 million people globally, including at least 15 million in Europe. Roughly half of these patients have LVEF ≥40%, a group often burdened by comorbidities such as CKD, hypertension, and atrial fibrillation, all of which contribute to increased hospitalizations and mortality. Despite the growing prevalence, treatment options remain limited, and this population is projected to represent the majority of heart failure hospitalizations in the near future.
The study is part of the ongoing MOONRAKER program — one of the largest phase III study initiatives in heart failure to date — enrolling more than 15,000 patients and designed to provide a comprehensive evaluation of finerenone across a wide range of patient populations and clinical settings.
The MOONRAKER program comprises the completed phase III FINEARTS-HF study, along with the ongoing investigator-sponsored collaborative studies REDEFINE-HF, CONFIRMATION-HF, and FINALITY-HF.
On the CKD side, the THUNDERBALL program comprises completed phase III studies — FIDELIO-DKD, FIGARO-DKD, FIND-CKD, and FINE-ONE — along with the phase II CONFIDENCE study and ongoing phase III pediatric studies FIONA and FIONA-OLE.
Earlier this month, finerenone achieved the primary endpoint in the late-stage FIND-CKD study, marking a key milestone in expanding its use to patients with non-diabetic CKD.
Kerendia is one of the top drugs for Bayer and generated sales of €829 million in 2025, up 79% from 2024.
BAYRY Looks to Strengthen Portfolio
Bayer’s recent turnaround has been phenomenal and the company is now looking to expand its diverse portfolio.
Shares of Bayer have surged 84.4% over the past year compared with the industry’s gain of 8.6%.
Image Source: Zacks Investment Research
Its new products, such as prostate cancer drugs Nubeqa and Kerendia, continue to maintain their impressive momentum in the Pharmaceutical division.
The strong performance of these drugs makes up for the decline in sales of oral anticoagulant Xarelto, which is co-developed with Johnson & Johnson (JNJ - Free Report) .
Xarelto is marketed by Johnson & Johnson in the United States. Bayer earns license revenues from JNJ for Xarelto sales in the United States.
Eylea sales continue to face pressure from generics. The introduction of Eylea 8 mg, with its extended dosing intervals, has partially offset the decline and supported overall performance.
Please note that Bayer’s HealthCare unit co-develops Eylea with Regeneron (REGN - Free Report) , which records net product sales of Eylea in the United States. BAYRY records net product sales of Eylea outside the country. REGN records its share of profits/losses in connection with the sales of Eylea outside the United States.
Label expansion of key drugs and approval of additional drugs will further boost sales from this business. The recent FDA approval of elinzanetant for the treatment of moderate to severe menopause-related vasomotor symptoms, under the brand name Lynkuet, is a significant boost for the company.
The FDA recently granted accelerated approval to Hyrnuo (sevabertinib) for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer whose tumors have human epidermal growth factor receptor 2 tyrosine kinase domain-activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
Encouraging developments in the Roundup litigation have lifted investor sentiment. Bayer acquired the Roundup weedkiller through its 2018 buyout of Monsanto. Since then, the company has faced numerous lawsuits alleging that Monsanto’s herbicide, whose active ingredient is glyphosate, caused cancer.
Monsanto has reached an agreement with leading plaintiffs’ law firms on a proposed class settlement related to the glyphosate litigation. This follows the U.S. Supreme Court’s decision to hear Bayer’s case, marking a crucial development for the company.
BAYRY expects litigation impacts to burden its cash position in 2026.
Zacks Rank
Bayer currently carries a Zacks Rank #5 (Strong Sell).
View the Zacks #1 Rank List
Image: Bigstock
Bayer Wins EC Approval to Expand Kerendia in Heart Failure Treatment
Key Takeaways
Bayer (BAYRY - Free Report) announced that the European Commission ("EC") has approved a label expansion of Kerendia (finerenone) in the European Union ("EU").
The drug, a selective, non-steroidal mineralocorticoid receptor antagonist (nsMRA), is now approved in the EU for the treatment of adults with heart failure (HF) with left ventricular ejection fraction (LVEF) ≥40%, i.e. HF with mildly reduced (HFmrEF) or preserved LVEF (HFpEF).
We remind investors finerenone is already marketed as Kerendia—or as Firialta in certain countries—and is approved in more than 100 countries, including China, Europe, Japan, and the United States, for the treatment of adults with chronic kidney disease (CKD) associated with type II diabetes (T2D).
Bayer Aktiengesellschaft Price, Consensus and EPS Surprise
Bayer Aktiengesellschaft price-consensus-eps-surprise-chart | Bayer Aktiengesellschaft Quote
More on BAYRY’s Kerendia’s Latest Label Expansion
The EC’s decision is based on results from the phase III FINEARTS-HF study, which demonstrated that finerenone significantly reduced the composite endpoint of cardiovascular death and total (first and recurrent) heart failure events, including hospitalizations and urgent visits, compared with placebo on top of standard therapy.
Heart failure affects more than 64 million people globally, including at least 15 million in Europe. Roughly half of these patients have LVEF ≥40%, a group often burdened by comorbidities such as CKD, hypertension, and atrial fibrillation, all of which contribute to increased hospitalizations and mortality. Despite the growing prevalence, treatment options remain limited, and this population is projected to represent the majority of heart failure hospitalizations in the near future.
The study is part of the ongoing MOONRAKER program — one of the largest phase III study initiatives in heart failure to date — enrolling more than 15,000 patients and designed to provide a comprehensive evaluation of finerenone across a wide range of patient populations and clinical settings.
The MOONRAKER program comprises the completed phase III FINEARTS-HF study, along with the ongoing investigator-sponsored collaborative studies REDEFINE-HF, CONFIRMATION-HF, and FINALITY-HF.
On the CKD side, the THUNDERBALL program comprises completed phase III studies — FIDELIO-DKD, FIGARO-DKD, FIND-CKD, and FINE-ONE — along with the phase II CONFIDENCE study and ongoing phase III pediatric studies FIONA and FIONA-OLE.
Earlier this month, finerenone achieved the primary endpoint in the late-stage FIND-CKD study, marking a key milestone in expanding its use to patients with non-diabetic CKD.
Kerendia is one of the top drugs for Bayer and generated sales of €829 million in 2025, up 79% from 2024.
BAYRY Looks to Strengthen Portfolio
Bayer’s recent turnaround has been phenomenal and the company is now looking to expand its diverse portfolio.
Shares of Bayer have surged 84.4% over the past year compared with the industry’s gain of 8.6%.
Image Source: Zacks Investment Research
Its new products, such as prostate cancer drugs Nubeqa and Kerendia, continue to maintain their impressive momentum in the Pharmaceutical division.
The strong performance of these drugs makes up for the decline in sales of oral anticoagulant Xarelto, which is co-developed with Johnson & Johnson (JNJ - Free Report) .
Xarelto is marketed by Johnson & Johnson in the United States. Bayer earns license revenues from JNJ for Xarelto sales in the United States.
Eylea sales continue to face pressure from generics. The introduction of Eylea 8 mg, with its extended dosing intervals, has partially offset the decline and supported overall performance.
Please note that Bayer’s HealthCare unit co-develops Eylea with Regeneron (REGN - Free Report) , which records net product sales of Eylea in the United States. BAYRY records net product sales of Eylea outside the country. REGN records its share of profits/losses in connection with the sales of Eylea outside the United States.
Label expansion of key drugs and approval of additional drugs will further boost sales from this business. The recent FDA approval of elinzanetant for the treatment of moderate to severe menopause-related vasomotor symptoms, under the brand name Lynkuet, is a significant boost for the company.
The FDA recently granted accelerated approval to Hyrnuo (sevabertinib) for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer whose tumors have human epidermal growth factor receptor 2 tyrosine kinase domain-activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
Encouraging developments in the Roundup litigation have lifted investor sentiment. Bayer acquired the Roundup weedkiller through its 2018 buyout of Monsanto. Since then, the company has faced numerous lawsuits alleging that Monsanto’s herbicide, whose active ingredient is glyphosate, caused cancer.
Monsanto has reached an agreement with leading plaintiffs’ law firms on a proposed class settlement related to the glyphosate litigation. This follows the U.S. Supreme Court’s decision to hear Bayer’s case, marking a crucial development for the company.
BAYRY expects litigation impacts to burden its cash position in 2026.
Zacks Rank
Bayer currently carries a Zacks Rank #5 (Strong Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.